GlassScriptPhysician profile
Stephen K Seecharan
NPI 1821160664
$3,794.16
in general payments reported to CMS, 2019-2025
32 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $78.28 · 2021: $674 · 2022: $705 · 2023: $690 · 2024: $441 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,195.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $548.60 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $345.35 | 2019-2023 | |
| Amgen INC. | $334.98 | 2021-2025 | Evenity, Prolia, Prolia |
| Tandem Diabetes Care, INC. | $329.22 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $321.81 | 2020-2025 | Jardiance |
| Mannkind Corporation | $203.82 | 2021-2024 | Afrezza |
| Novo Nordisk INC | $203.12 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $193.49 | 2019-2023 | Arexvy |
| Xeris Pharmaceuticals, INC. | $190.36 | 2022-2025 | Gvoke Hypopen, Keveyis |
| Novartis Pharmaceuticals Corporation | $167.45 | 2024-2025 | |
| Insulet Corporation | $157.93 | 2021-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $92.19 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $91.78 | 2019-2023 | Breztri |
| Abbvie INC. | $62.97 | 2021-2025 | Synthroid |
| Abbott Laboratories | $62.82 | 2022-2024 | Freestyle Libre 3 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $61.07 | 2025 | Mycapssa |
| Bayer Healthcare Pharmaceuticals INC. | $55.80 | 2023-2024 | |
| Dexcom, INC. | $43.39 | 2024-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $41.63 | 2023-2025 | Korlym |
| Medtronic, INC. | $40.64 | 2024-2025 | Minimed 780g |
| Clarus Therapeutics INC. | $38.05 | 2021 | |
| Ibsa Pharma INC. | $30.80 | 2021 | |
| Amarin Pharma, INC. | $25.61 | 2021 | |
| Sequel Med Tech, LLC | $22.15 | 2025 | Twiist |
| Grt US Holding, INC. | $21.97 | 2022 | |
| Beta Bionics, INC. | $20.57 | 2024 | Ilet Bionic Pancreas |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.01 | 2021 | |
| Acella Pharmaceuticals, LLC | $16.64 | 2025 | NP Thyroid 60 |
| Amneal Pharmaceuticals LLC | $13.97 | 2025 | Unithroid |
| Radius Health, INC. | $13.60 | 2020 | |
| Pfizer INC. | $12.49 | 2019 | |
| Lifescan, INC. | $11.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Seecharan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.